Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.54 |
| ▸ | SKP1 | P63208 | 1/20 | 0.54 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.54 |
| ▸ | ACACB | O00763 | 9/20 | 0.51 |
| ▸ | ACACA | Q13085 | 9/20 | 0.51 |
| ▸ | LDHA | P00338 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6066394 | 0.89 | CKS1B (0.54) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL803332 | 0.85 | CKS1B (0.56) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL16691325 | 0.83 | CKS1B (0.52) | CKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL4528922 | 0.83 | CKS1B (0.59) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL12916519 | 0.82 | GPR119 (0.57) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL4116060 | 0.80 | CKS1B (0.64) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL32665119 | 0.80 | CKS1B (0.53) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL25085708 | 0.79 | CKS1B (0.57) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL18886506 | 0.79 | GPR119 (0.61) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL29878611 | 0.79 | GPR119 (0.61) | CKS1BSKP1SKP2ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281873-A1 | COMPOUND AS PORCUPINE INHIBITOR AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2022-09-08 | — | — | US | disclosed |
| WO-2021004467-A1 | COMPOUND AS PORCUPINE INHIBITOR AND USE THEREOF | 南京明德新药研发有限公司 | 2021-01-14 | — | — | WO | disclosed |
| US-7067665-B2 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-06-27 | — | — | US | disclosed |
| US-6953857-B2 | Oxybenzamide derivatives useful for inhibiting factor Xa or viia | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-10-11 | — | — | US | disclosed |
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-28 | — | — | US | disclosed |
| EP-1349847-B1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| EP-1349847-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2003-10-08 | — | — | EP | disclosed |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002051831-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281873-A1 | COMPOUND AS PORCUPINE INHIBITOR AND USE THEREOF | PORCN, SLC6A1, SLC6A11 | CKS1B 3934/4885SKP1 1304/4885SKP2 2457/4885 |
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | F12, F11, F5 | CKS1B 2725/4885SKP1 1879/4885SKP2 3182/4885 |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | F9, F11, F5 | CKS1B 1806/4885SKP1 2262/4885SKP2 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.